2025-06-12-Jefferies-重播_我们华盛顿政策讨论的要点_8页_420kb

报告摘要

Summary of Jefferies Biotechnology Equity Research Report

1. Performance and Outlook

The biopharma sector underperformed in the first half of 2025 due to ongoing policy uncertainty, including tariffs, Most-Favored Nation (MFN) pricing, Medicaid cuts, and FDA-related issues. This uncertainty led to a 70-80% year-over-year decline in IPOs and follow-ons. The market is expected to stabilize in the second half as clarity emerges on MFN/tariff negotiations, FDA approvals continue on schedule, and merger and acquisition (M&A) activity increases, potentially driving stock prices higher.

2. Policy and Large-Cap Dynamics

MFN and Tariffs: Legislation for MFN is unlikely in the near term, but the administration may use tariffs as leverage for "political wins" with drug companies to secure commitments on fair pricing. Trump's executive order (EO) issued on June 11 gives the HHS Secretary 30 days to set drug target prices, potentially leading to announcements this week.
Medicaid Cuts: Potential cuts from the Big Beautiful Bill could impact large-cap names like Gilead (GILD) and Vertex (VRTX), which have significant Medicaid exposure (20-25%). The reconciliation process involves Senate passage and reconciliation by September 30 to avoid restarting the process.

3. Small-Cap Dynamics

M&A Activity: M&A is expected to increase in H2 as markets stabilize and valuations clarify, driven by timely FDA approvals and the need for companies to compete internationally.
China-Based Biotech: Rising reliance on Chinese in-licensing benefits large pharma but hinders US small-caps in M&A. The Trump administration is scrutinizing China-based clinical trial data, and the FDA aims to speed up approvals using AI and reduced animal testing, which could benefit US innovation and competitiveness.

4. Key Catalysts to Watch

Clarity on MFN/tariff issues.
Senate passage of the budget bill (before July 4).
FDA approval timelines and M&A transactions.
Tariff discussions from the 232 investigation, particularly as negotiation leverage.

5. Risks and Uncertainties

Policy risks: Ongoing ambiguity in tariffs, MFN, Medicaid cuts, and trade negotiations.
Market volatility: Valuation shifts and regulatory delays could impact performance.
Geopolitical factors: Increased scrutiny on Chinese-based data and global pricing parity.
Timeline risks: Delays in budget reconciliation or FDA processes could extend uncertainty.

展开完整摘要